Price Reductions for Third Transitional Cycle
Summary of 1 August 2012 Price Reductions for Third Transitional Cycle by Drug / Manner of Administration / Weighted Average Percentage Reduction.
| Drug | Manner of Administration | Weighted Average Percentage Reduction |
|---|---|---|
| Amisulpride | Oral | 18.27% |
| Bisoprolol | Oral | 18.75% |
| Cefalotin | Injection | 16.99% |
| Doxorubicin | Injection/intravesical | 32.97% |
| Escitalopram | Oral | 36.76% |
| Levetiracetam | Oral | 14.15% |
| Meloxicam | Oral | 23.62% |
| Mitozantrone | Injection | 18.25% |
| Ondansetron | Injection | 77.25% |
| Oxaliplatin | Injection | 51.76% |
| Oxybutynin | Oral | 11.25% |
| Perindopril with Indapamide | Oral | 11.59% |
| Prochlorperazine | Oral | 25.55% |
For further information about specific prices for pharmaceutical items please see the Federal Register of Legislative Instruments (FRLI): www.comlaw.gov.au/Details/F2012L00931
Last updated
1 August 2012